ArticlePDF Available

Cause of Androgenic Alopecia: Crux of the Matter

Authors:

Abstract and Figures

What is wrong with the current understanding of etiopathogenesis of androgenic alopecia (AGA)? What is the most important question to ask to understand AGA? Why is that question skimped? Which findings are interpreted incorrectly? Is there anything that has not been discerned about AGA until today? What are the deceptive factors for investigators? Is it possible to snap the whole view uninterruptedly in one clear picture? Answers and an overview with fresh perspectives are provided.This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. http://creativecommons.org/licenses/by-nc-nd/3.0. American Society of Plastic Surgeons.
Content may be subject to copyright.
www.PRSGO.com 1
The reader would probably agree that the fol-
lowing are generally recognized as safe to
claim with regard to androgenic alopecia
(AGA) and contribute to androgenic theory:
• 5-alpha reductase enzyme activity, which con-
verts testosterone to dihydrotestosterone (DHT),
increases in balding scalp,1
• DHT increases in balding scalp,2,3
• Number of DHT receptors on the hair follicles
increases in balding scalp,4
• Blocking conversion of testosterone to DHT
delays progression of AGA.5
Based on these findings, DHT is held responsible
for miniaturization of hair follicles in AGA.6 How-
ever, as DHT is a more potent form of testosterone
and androgens are expected to convert hair follicles
from vellus to terminal not the other way around,
this inference gives rise to a paradox. In a review
article, Randall says, “How one type of circulating
hormone has such contrary effects on a single tissue
depending on its body site is not clear; this biologi-
cal paradox alone makes androgen action in hair fol-
licles very intriguing.”7 It is indeed so.
Androgen-dependent/independent and andro-
gen-sensitive/insensitive hair follicle concepts have
been used to explain the opposite effects of andro-
gens on hair follicles at different body sites.6–8 Ac-
cording to these concepts, nonbalding scalp hair is
designated as androgen independent and androgen
insensitive, whereas balding scalp hair as androgen
independent but androgen sensitive.8 Here, there
is a point that deserves attention. Androgen-de-
pendent/independent hair follicle concept treats
the whole scalp as a single body site, which stands
to reason. Scalp hair, either balding or nonbalding,
is considered androgen independent because they
grow in the absence of androgens as opposed to, for
example, axillary or pubic hair. However, androgen-
sensitive/insensitive hair follicle concept divides the
scalp into 2 sites as androgen-sensitive and andro-
gen-insensitive hair-bearing areas. This arbitrary di-
vision of scalp is discomforting in the first place and
inappropriateness of the concept becomes evident
as it is questioned further.
As stated above, DHT is accepted to be the an-
drogen that binds to androgen receptors and effects
follicular miniaturization. Along with other findings,
this conclusion is based on the finding of increased
levels of DHT in balding scalp compared with non-
balding scalp. Unless DHT levels in balding scalp
are equal to DHT levels in nonbalding scalp, follicu-
lar miniaturization in AGA cannot be considered a
Received for publication July 13, 2013; accepted September 6,
2013.
Copyright © 2013 The Authors. Published by Lippincott
Williams & Wilkins on behalf of The American Society of
Plastic Surgeons. PRS Global Open is a publication of the
American Society of Plastic Surgeons. This is an open-access
article distributed under the terms of the Creative Commons
Attribution-NonCommercial-NoDerivatives 3.0 License,
where it is permissible to download and share the work
provided it is properly cited. The work cannot be changed in
any way or used commercially.
DOI: 10.1097/GOX.0000000000000005
From Ankara, Turkey.
Summary: What is wrong with the current understanding of etiopatho-
genesis of androgenic alopecia (AGA)? What is the most important question
to ask to understand AGA? Why is that question skimped? Which findings
are interpreted incorrectly? Is there anything that has not been discerned
about AGA until today? What are the deceptive factors for investigators?
Is it possible to snap the whole view uninterruptedly in one clear picture?
Answers and an overview with fresh perspectives are provided. (Plast Reconstr
Surg Glob Open 2013;1:e64; doi: 10.1097/GOX.0000000000000005; Published
online 28 October 2013.)
Emin Tuncay Ustuner, MD
Cause of Androgenic Alopecia: Crux of
the Matter
Disclosure: The author holds a patent on prevention
and treatment of male pattern baldness (U.S. Patent
No.7914548). The Article Processing Charge was paid
for by the author.
Cause of Androgenic Alopecia
Ustuner
xxx
xxx
XXX
Mythili
Plastic & Reconstructive Surgery-Global Open
2013
XXX
Special Topic
10.1097/GOX.0000000000000005
6September2013
13July2013
(c) 2013 The Authors. Published by Lippincott Williams & Wilkins on behalf of The Amer-
ican Society of Plastic Surgeons. PRS Global Open is a publication of the American Society
of Plastic Surgeons.
SPECIAL TOPIC
PRS GO 2013
2
matter of sensitivity to androgens. The amount of
androgen is not the same in the so-called androgen-
insensitive area.
In a relatively recent review article, the role of
androgens in the pathophysiology of AGA is docu-
mented by Kaufman.6 Kaufman says, “In men with
MPHL (male pattern hair loss), follicular miniatur-
ization is caused by an inherited sensitivity of scalp
hair follicles to normal levels of circulating andro-
gens.” “Thus, it appears that in balding men DHT
binds to androgen receptors in susceptible hair folli-
cles and, by an unknown mechanism, activates genes
responsible for follicular miniaturization.”
Kaufman tries to put it right saying sensitivity to
“normal levels of circulating androgens” to no avail.
It helps correct the terminology from one point of
view only and obviously does not bring in an expla-
nation to the opposite effects of androgens on bald-
ing scalp hair follicles vs hair follicles at other body
sites. If there is sensitivity to normal levels of circu-
lating androgens and the resulting product of this
sensitivity is DHT, an overall pronounced effect is
expected not an opposite effect. DHT is a stronger
form of testosterone.
Androgen sensitivity concept is not only an inept
concept to explain the role of androgens in AGA
but it is also confusing and misleading its adopters
after some dubious “genes responsible for follicular
miniaturization” and “an unknown mechanism” that
activates them. Worst of all, it skimps the most criti-
cal question and prevents it from standing forward,
which is:
• Why does DHT (or 5-alpha reductase enzyme ac-
tivity) increase in balding scalp?
This question requires a solid answer and has pri-
ority over the other crucial questions that are as fol-
lows:
• How does DHT cause hair loss while exactly the
opposite effect is expected?
• Why does balding (or increase in DHT levels) oc-
cur only at the top of the head?
If these questions are considered fair questions, a
valid theory on the etiology of AGA has to be able to
answer all of these questions.
I introduced a new theory in 2008.9 It does ac-
complish this hard task adroitly; moreover, it is in
agreement with all findings in connection with AGA.
The mechanism of AGA is thought to be highly com-
plex.10 However, this theory provides a new viewpoint
from which it seems to be quite simple. According to
the theory, pressure on the hair follicles created by
the weight of the scalp is the cause of AGA. Total
weight of the skin, subcutaneous connective tissue,
and galea are operative. With sandwiched fat tis-
sue and fibrous connections between the skin and
galea, all of these components of the scalp form a
combined structure that sits on the cranial bones
much like a separate structure movable on the cra-
nial bones due to the intervening loose areolar tis-
sue. Hair follicles are compressed by the skin against
the calvarial bones. This theory is uniquely capable
of explaining all related phenomena and paradoxes.
In summary, the theory points out that the pres-
sure on the hair follicles is buffered by the surround-
ing subcutaneous fat tissue and young dermis that is
capable of keeping itself well hydrated. As one ages,
thickness of the subcutaneous fat tissue and the vol-
ume of the dermis decreases,11,12 that is, the buffer
decreases and consequently the pressure on the hair
follicles increases. Another factor that is well known
to cause thinning of subcutaneous fat tissue much
more rapidly than aging is testosterone.13–16 With
the onset of puberty, subcutaneous fat tissue starts
to decrease instantaneously at an early age in the
male due to increase in testosterone levels.17,18 Estro-
gen protects the cushioning tissues until after meno-
pause in the female.19–24 And, testosterone effected
reduction in subcutaneous fat tissue normally does
not happen in the female at all.
On the other hand, it has been shown that the
downward growth of early anagen follicle occurs by
growth pressure.25,26 It has to work against the com-
pressive force described above. As the cushion reduc-
es, the hair follicle needs to strive against a higher
pressure to reach its terminal follicle size. More an-
drogen is demanded to promote the growth. This is a
local demand, and there is a mechanism for increas-
ing the effect of androgens locally without raising
systemic androgen levels. 5-alpha reductase enzyme
activity increases at the locale and converts more tes-
tosterone to DHT, which has severalfold greater af-
finity for androgen receptors than testosterone. And,
DHT increases locally. The sequence of reactions
Fig. 1. The vicious circle in AGA.
Ustuner Cause of Androgenic Alopecia
3
does not end here. Increased DHT causes further
erosion of the subcutaneous fat tissue around the
hair follicle.27–29 A vicious circle is created (Fig. 1).
There is not another theory that reasonably
and satisfactorily explains hair loss in AGA without
ascribing a function to DHT that is opposite to its
known function. DHT increases to help the hair fol-
licle forge ahead deeper to reach its normal terminal
follicle size in the face of increased pressure due to
decrease in cushioning tissues. As long as the pres-
sure on the follicle is adequately buffered, a base
androgen level is enough and required for healthy
hair growth.30 As the cushion decreases, the balance
is lost at some point and the vicious circle is initi-
ated. Increased DHT promotes hair growth proba-
bly mainly by stimulating mitosis in the early anagen
follicle. However, increased growth pressure due to
advanced mitosis cannot overcome the compressing
pressure on the hair follicle but speeds up and short-
ens the anagen phase. Hair follicle cannot grow to its
full size and becomes smaller and smaller with each
cycle along with the increasing pressure on the hair
follicle. Hair follicle miniaturization, that is, termi-
nal to vellus conversion, takes place, anagen to telo-
gen ratio reduces, and hair loss increases.
A reaction-dubbed microinflammation around
the bulge region of individual hair follicles in bald-
ing scalp has been presumed a causative factor in
AGA,31,32 but most likely it is evidence for the new
theory. A reaction that is much milder than the in-
flammation seen in a typical inflammatory scarring
alopecia and takes place at the site of mitosis suggests
scavenging of products resulting from inefficient mi-
tosis rather than a factor in the etiology of AGA.
Finally, if the pressure created by the weight of the
scalp causes the hair loss in AGA, which is claimed
by the theory, it is expected that the hair at the top
of the head is lost. This is exactly what happens in
AGA. Although the conformity is manifest and there
is an appreciable relation between the shape of the
cranium and the hair loss area in AGA, a few points
have to be observed so as not to get confused.
It is better to examine only the last-stage AGA cas-
es observing and evaluating the hair loss area from
this theory point of view for the first time. AGA is a
progressive condition, and there are several factors
that can be effective on where hair loss starts and
how it progresses in different individuals. Observing
more hair loss at presumedly lower pressure areas
than higher pressure areas in intermediate-stage
AGA cases can be deceptive and is the most common
source of confusion.
An example of the relation between the shape
of the cranium and the hair loss area is shown in
Figure 2. Outlines of the side views and back views of
2 heads are seen. The only difference between the 2
heads is the shape of the back of the calvarium. One
of them is rather rounded in shape (Fig. 2A), where-
as the other is more like 2 oblique surfaces that meet
at an obtuse angle (Fig. 2C). Hair loss area extends
down to where the back of the upright head contacts
with a vertical line (red line in the drawing). The
pressure is relieved below this contact site as the scalp
turns away from the vertical direction. Most of the
time the point of pressure relief is located at a lower
level in the latter type (Fig. 2D) than in the former
(Fig. 2B), so that looking from behind the person a
bigger bald area is seen in the latter. This finding is a
strong revealing finding for the new theory but may
be misleading if it is not interpreted correctly.
Also, the structure of the scalp has to be given due
consideration during the evaluation of hair loss area
in relation to the shape of the cranium. For example,
even if the back of the head is precisely straight and
vertical when the head is upright, the weight of the
scalp still creates pressure on the hair follicles at the
back of the head although the direction of the gravi-
tational force is vertical, that is, parallel to the back
of the head (the same applies for the hair follicles
within the contact site with the vertical line in the
previous example). Galea aponeurotica is a tough
nonelastic structure and there are dense, nonelastic
fibrous attachments between the galea and the skin
of the scalp. Downward pull in the vertical direction
Fig. 2. The relation between the shape of the cranium and the hair loss area in AGA is a proof
for the validity of the new theory. Hair loss extends to where a vertical line makes contact
with the back of the upright head. Depending on the shape of the back of the head, this
point may be at a higher (A, B) or lower (C, D) location.
PRS GO 2013
4
on the skin of the back of the head is opposed by
these nonelastic fibrous attachments. The resulting
net force is toward the calvarium and it compresses
the hair follicles (Fig. 3). Therefore, in such cases,
hair loss area is expected to extend down usually to
the level of the border of the galea with the occipita-
lis muscle at the back of the head.
One more important point that should be re-
garded is that the force of downward pull caused by
the gravity on the scalp skin is not distributed equally
around the circumference of the head (Fig. 4). As
the ears are firmly fixed to the temporal bones, they
interrupt the soft-tissue continuity, shore up the soft
tissues above and around them, and assume the pull
of the soft tissues below. By contrast, scalp skin is con-
tinuous with the skin of the face between the ears and
eyes on both sides of the face, so that the weight of
the facial soft tissues adds to the pressure in the fron-
tal part of the scalp. The circumstances are similar
at the back of the head in terms of effective weights.
The weight of the soft tissues below the ear level at
the back of the head similarly adds to the pressure in
the vertex area as an extra weight compared with the
area above the ears. In most of the AGA cases, hair
loss starts at the frontal and/or vertex areas.
The new theory’s unparalleled ability to explain
even the details of the hair loss process and the for-
mation of the pattern in AGA is apparent.
In his review Trüeb10 states that genetic involve-
ment in AGA is pronounced, but no specific gene has
been identified yet and genetic predisposition to AGA
remains poorly understood. He continues, “We prob-
ably deal with a polygenic inheritance, dependent on
a combination of mutations, e.g. in or around the AR
(androgen receptor) gene affecting the expression of
the AR, and other genes controlling androgen levels.”
However, systemic androgen levels are normal in AGA,
DHT increases locally and the enzyme that converts
testosterone to DHT is 5-alpha reductase. In the same
review, Trüeb acknowledges that the genes encod-
ing the two 5-alpha reductase isoenzymes have been
shown not to be associated with AGA by Ellis et al.33
That is, although there are many findings that suggest
genetic involvement in AGA, DHT increase in AGA is
not an occurrence directly determined by genes.
It comes to the same question again: Why does
DHT increase in balding scalp? This is the crux of
the matter.
Fig. 3. Fat tissue and brous bands between the skin and galea of the scalp in a hypotheti-
cal case wherein the back of the calvarium is vertical and straight are depicted. (A), If there
were no gravity, there would not be a downward pull, whereas (B) in the presence of gravity,
downward pull on the skin at the back of the head is directed inward because of the inelastic
brous bands connecting the skin to the inelastic galea and resisting the gravity.
Fig. 4. Anatomy is a determining factor on the magnitude of
the downward pull at dierent parts of the scalp. Middle top
of the scalp is supported by the ears in contrast with the fron-
tal and vertex regions. Soft-tissue loads on the frontal and
vertex areas of the scalp are more than the soft-tissue load
on the middle top.
Ustuner Cause of Androgenic Alopecia
5
Since its introduction, the new theory has been
regarded with notable skepticism and resistance.
Simplifying a very complicated problem is probably
the only disadvantage of the theory. AGA has been
one of the biggest and most challenging problems
of the humankind. It has affected so many lives
throughout the human history and has been a dev-
astating condition for so many of the afflicted. It is
difficult to settle for any mechanism less than highly
complex. However, all natural phenomena that
seem to be complex look simpler if viewed from the
right standpoint.
Emin Tuncay Ustuner, MD
Ankara 06660, Turkey
E-mail: ustuneret@gmail.com
REFERENCES
1. Sawaya ME, Price VH. Different levels of 5alpha-reductase
type I and II, aromatase, and androgen receptor in hair
follicles of women and men with androgenetic alopecia. J
Invest Dermatol. 1997;109:296–300.
2. Schweikert HU, Wilson JD. Regulation of human hair
growth by steroid hormones. I. Testerone metabolism in
isolated hairs. J Clin Endocrinol Metab. 1974;38:811–819.
3. Dallob AL, Sadick NS, Unger W, et al. The effect of fi-
nasteride, a 5 alpha-reductase inhibitor, on scalp skin
testosterone and dihydrotestosterone concentrations
in patients with male pattern baldness. J Clin Endocrinol
Metab. 1994;79:703–706.
4. Hibberts NA, Howell AE, Randall VA. Balding hair follicle
dermal papilla cells contain higher levels of androgen re-
ceptors than those from non-balding scalp. J Endocrinol.
1998;156:59–65.
5. Kaufman KD, Olsen EA, Whiting D, et al. Finasteride
in the treatment of men with androgenetic alopecia.
Finasteride Male Pattern Hair Loss Study Group. J Am
Acad Dermatol. 1998;39(4, Part 1):578–589.
6. Kaufman KD. Androgens and alopecia. Mol Cell Endocrinol.
2002;198:89–95.
7. Randall VA. Androgens and human hair growth. Clin
Endocrinol (Oxf). 1994;40:439–457.
8. Stenn KS, Paus R. Controls of hair follicle cycling. Physiol
Rev. 2001;81:449–494.
9. Ustuner ET. Baldness may be caused by the weight of the
scalp: gravity as a proposed mechanism for hair loss. Med
Hypotheses 2008;71:505–514.
10. Trüeb RM. Molecular mechanisms of androgenetic alope-
cia. Exp Gerontol. 2002;37:981–990.
11. Levakov A, Vucković N, Dolai M, et al. Age-related skin
changes. Med Pregl. 2012;65:191–195.
12. Caso G, McNurlan MA, Mileva I, et al. Peripheral fat loss
and decline in adipogenesis in older humans. Metabolism
2013;62:337–340.
13. Xu XF, De Pergola G, Björntorp P. Testosterone increases
lipolysis and the number of beta-adrenoceptors in male
rat adipocytes. Endocrinology 1991;128:379–382.
14. Frederiksen L, Højlund K, Hougaard DM, et al.
Testosterone therapy decreases subcutaneous fat and
adiponectin in aging men. Eur J Endocrinol. 2012;166:
469–476.
15. Dieudonne MN, Pecquery R, Leneveu MC, et al. Opposite
effects of androgens and estrogens on adipogenesis in rat
preadipocytes: evidence for sex and site-related specifici-
ties and possible involvement of insulin-like growth factor
1 receptor and peroxisome proliferator-activated recep-
tor gamma2. Endocrinology 2000;141:649–656.
16. Corbould A. Chronic testosterone treatment induces se-
lective insulin resistance in subcutaneous adipocytes of
women. J Endocrinol. 2007;192:585–594.
17. Shen W, Punyanitya M, Silva AM, et al. Sexual dimor-
phism of adipose tissue distribution across the lifespan:
a cross-sectional whole-body magnetic resonance imaging
study. Nutr Metab (Lond). 2009;6:17.
18. Enzi G, Gasparo M, Biondetti PR, et al. Subcutaneous and
visceral fat distribution according to sex, age, and over-
weight, evaluated by computed tomography. Am J Clin
Nutr. 1986;44:739–746.
19. Brincat MP, Baron YM, Galea R. Estrogens and the skin.
Climacteric 2005;8:110–123.
20. Hall G, Phillips TJ. Estrogen and skin: the effects of es-
trogen, menopause, and hormone replacement therapy
on the skin. J Am Acad Dermatol. 2005;53:555–568; quiz
569–572.
21. Raine-Fenning NJ, Brincat MP, Muscat-Baron Y. Skin ag-
ing and menopause: implications for treatment. Am J Clin
Dermatol. 2003;4:371–378.
22. Shu YY, Maibach HI. Estrogen and skin: therapeutic op-
tions. Am J Clin Dermatol. 2011;12:297–311.
23. Archer DF. Postmenopausal skin and estrogen. Gynecol
Endocrinol. 2012;28(Suppl 2):2–6.
24. Van Pelt RE, Gozansky WS, Hickner RC, et al. Acute
modulation of adipose tissue lipolysis by intravenous es-
trogens. Obesity (Silver Spring) 2006;14:2163–2172.
25. Magerl M, Tobin DJ, Müller-Röver S, et al. Patterns of pro-
liferation and apoptosis during murine hair follicle mor-
phogenesis. J Invest Dermatol. 2001;116:947–955.
26. Paus R, Müller-Röver S, Van Der Veen C, et al. A com-
prehensive guide for the recognition and classification
of distinct stages of hair follicle morphogenesis. J Invest
Dermatol. 1999;113:523–532.
27. Gupta V, Bhasin S, Guo W, et al. Effects of dihydrotes-
tosterone on differentiation and proliferation of hu-
man mesenchymal stem cells and preadipocytes. Mol Cell
Endocrinol. 2008;296:32–40.
28. Xu X, De Pergola G, Björntorp P. The effects of andro-
gens on the regulation of lipolysis in adipose precursor
cells. Endocrinology 1990;126:1229–1234.
29. Singh R, Artaza JN, Taylor WE, et al. Androgens stimulate
myogenic differentiation and inhibit adipogenesis in C3H
10T1/2 pluripotent cells through an androgen receptor-
mediated pathway. Endocrinology 2003;144:5081–5088.
30. Glaser RL, Dimitrakakis C, Messenger AG. Improvement
in scalp hair growth in androgen-deficient women treat-
ed with testosterone: a questionnaire study. Br J Dermatol.
2012;166:274–278.
31. Jaworsky C, Kligman AM, Murphy GF. Characterization of
inflammatory infiltrates in male pattern alopecia: impli-
cations for pathogenesis. Br J Dermatol. 1992;127:239–246.
32. Mahé YF, Michelet JF, Billoni N, et al. Androgenetic alope-
cia and microinflammation. Int J Dermatol. 2000;39:576–584.
33. Ellis JA, Stebbing M, Harrap SB. Genetic analysis of male
pattern baldness and the 5alpha-reductase genes. J Invest
Dermatol. 1998;110:849–853.
... enzymatic activity of 5-α reductase, responsible for the conversion of testosterone to dihydrotestosterone (DHT), is elevated in the scalp affected by balding. Consequently, increasing DHT levels in the balding scalp, accompanied by an augmentation in the number of DHT receptors on the hair follicles in that region, eventually lead to the miniaturization of hair follicles [62,63]. Finasteride, as the sole FDA-approved drug currently available, inhibits 5-α reductase to diminish the production of dihydrotestosterone (DHT), emphasizing the importance of investigating potential interventions aimed at mitigating androgenic alopecia (AGA) by targeting DHT. ...
... The enzymatic activity of 5-α reductase, responsible for the conversion of testosterone to dihydrotestosterone (DHT), is elevated in the scalp affected by balding. Consequently, increasing DHT levels in the balding scalp, accompanied by an augmentation in the number of DHT receptors on the hair follicles in that region, eventually lead to the miniaturization of hair follicles [62,63]. Finasteride, as the sole FDA-approved drug currently available, inhibits 5-α reductase to diminish the production of dihydrotestosterone (DHT), emphasizing the importance of investigating potential interventions aimed at mitigating androgenic alopecia (AGA) by targeting DHT. ...
Article
Full-text available
Alopecia, a prevalent yet challenging condition with limited FDA-approved treatments which is accompanied by notable side effects, necessitates the exploration of natural alternatives. This study elucidated the hair growth properties of Gynostemma pentaphyllum leaf hydrodistillate (GPHD) both in vitro and in vivo. Furthermore, damulin B, a major component of GPHD, demonstrated hair growth-promoting properties in vitro. Beyond its established anti-diabetic, anti-obesity, and anti-inflammatory attributes, GPHD exhibited hair growth induction in mice parallel to minoxidil. Moreover, it upregulated the expression of autocrine factors associated with hair growth, including VEGF, IGF-1, KGF, and HGF. Biochemical assays revealed that minoxidil, GPHD, and damulin B induced hair growth via the Wnt/β-catenin pathway through AKT signaling, aligning with in vivo experiments demonstrating improved expression of growth factors. These findings suggest that GPHD and damulin B contribute to the hair growth-inducing properties of dermal papilla cells through the AKT/β-catenin signaling pathway.
... It is characterized by progressive thinning of the hair, primarily in the frontal and vertex regions in males, and a diffuse thinning over the crown in females. AGA is a hereditary condition that affects up to 50% of men and women by the age of 50, making it a significant cosmetic and psychological concern for many individuals [2]. While the exact pathophysiology of AGA remains partially understood, it is primarily driven by genetic predisposition and hormonal factors. ...
Article
Full-text available
Androgenetic alopecia (AGA) is a prevalent and progressive hair disorder affecting both men and women. It is characterized by the miniaturization of hair follicles, reduced hair density, and alterations in scalp conditions. Accurate assessment of hair growth parameters is crucial for understanding the progression of AGA and evaluating the efficacy of treatment interventions. This study aimed to develop and validate robust methodologies for assessing critical endpoints related to hair growth and scalp health. These standardized methods provide a reliable framework for future efficacy studies targeting AGA and similar hair disorders. This method development and standardization study utilized an observational, non-interventional, open-label design and included 25 subjects diagnosed with AGA. Non-invasive techniques were employed to evaluate various hair parameters, including hair regrowth (vellus hair count), hair density, thickness, and total hair count, using the CASLite Nova phototrichogram software and Image-Pro software for precise analysis. Hair length was assessed using a calibrated ruler, while hair tensile strength was measured with the Testronix tensile hair tester instrument. Additional parameters, such as quantitative hair keratin levels and scalp keratin levels, were analyzed to provide an understanding of hair health. Baldness severity was evaluated using the Norwood-Hamilton scoring system for male participants and the Ludwig scoring system for female participants. Furthermore, a detailed visual hair distribution analysis was conducted. To minimize inter-evaluator variability, standardized training sessions were conducted, ensuring consistency across assessments. The reliability of the scoring systems was confirmed using the Fleiss Multirater Kappa test.
... Alopecia, often known as hair loss, is a complicated phenomenon that may originate from a congenital or genetic illness or may appear later in life. 1 The most common form of alopecia is androgenetic alopecia (AGA), which affects approximately 50% of the global population regardless of gender, age, and ethnicity. 2,3 It is a condition marked by an increase in the activity and production of the hormone dihydrotestosterone (DHT), 4 facilitated by the enzyme 5α-reductase 5 . It was found that the conversion of testosterone to its more potent version, DHT, causes hair follicle shrinkage and an increase in hair thinning. ...
Article
Full-text available
Objectives Carica papaya has been widely used commercially for skin care due to its therapeutic benefits. The potential of its flower to promote hair growth has been traditionally recognized in other countries but not in the Philippines. In this study, we explored the effect of various extracts of C. papaya flower in the biological activities associated with hair loss, including 5α-reductase inhibition and antioxidation, as well as identified the putative compounds present in the most potent extract. Methods The flowers of C. papaya were macerated separately with ethanol, ethyl acetate, and hexane to obtain their corresponding crude extracts. These extracts were subjected to antioxidant tests via 2,2′-diphenyl-1-picrylhydrazyl (DPPH), and ferric-reducing antioxidant power (FRAP) assays. The total phenolic and flavonoid contents (TPC and TFC) of the crude extracts were determined, as well as the ability of the extracts to inhibit 5α-reductase. The compounds present in the most potent extract were determined using ultraperformance liquid chromatography quadrupole time of flight mass spectrometer (UPLC/MS-QToF). Results Ethyl acetate extract displayed significantly higher DPPH activity (0.001755 ± 0.00092 ascorbic acid equivalent antioxidant capacity) and 5α-reductase inhibitory activity (115.18 ± 11.61 mg dutasteride/g) compared to ethanol (DPPH: p=0.0121; 5α-reductase: p=0.0016) and hexane (DPPH: p=0.0038; 5α-reductase: p<0.0001) extracts. Similarly, ethyl acetate extract gave the highest FRAP (0.4842 ± 0.0936 mg ascorbic acid/g) activity, TFC (0.0403 mg quercetin/g), and TPC (0.0463 mg gallic acid/g) among the extracts. Forty-nine compounds were annotated in the ethyl acetate extract, with seven (7) putatively identified as fatty acids (9-hydroxy-10,12-pentadecadienoic acid, 9,12,15-octadecatrienoic acid), hydroxyflavone (5-methylkaempferol), alkaloid (allomatrine), dipeptide derivative (aurantiamide acetate), bufotalinin, and 6β-acetoxy-5-epilimonin based on the Traditional Chinese Medicine Library. Conclusion These results suggest that local C. papaya flowers can be a source of hair growth-promoting agents via their antioxidant and 5α-reductase inhibitory potential.
... Androgens, including testosterone and dihydrotestosterone (DHT), are known to affect the hair growth cycle, especially in androgen-sensitive areas such as the scalp, where they can lead to the miniaturization of hair follicles. 22,23 This hormonal interaction is a key element in the pathophysiology of androgenetic alopecia, where genetically predisposed individuals exhibit sensitivity to androgenic effects, leading to progressive hair thinning and loss. Beyond androgens, other hormonal factors such as thyroid hormones, growth hormone, and cortisol levels can also influence hair growth, with imbalances potentially leading to hair disorders, further emphasizing the critical role of hormonal homeostasis in hair health. ...
Article
Full-text available
Hair growth and its regulation are critical in biomedical research due to the widespread issue of hair loss. Understanding the cellular and molecular mechanisms of hair follicle development, cycling, and regeneration is essential for identifying therapeutic targets for hair growth disorders. This comprehensive literature review examined research on the biological pathways of hair follicle development, the role of the secretome in hair regeneration, and the efficacy of current hair loss treatments. Databases such as PubMed, Scopus, and Web of Science were meticulously searched for relevant studies, with a particular focus on the effects of the secretome on hair growth. The review highlights the significant role of hair follicle stem cells in wound healing through re-epithelialization and neogenesis, influenced by inflammatory cells. Exosomes from hair follicle mesenchymal stem cells containing lncRNA H19 enhanced diabetic wound healing by promoting cell proliferation and inhibiting pyroptosis. Hair follicle transplantation demonstrated the activation and differentiation of stem cells, with molecular signaling pathways between epithelial and mesenchymal cells being crucial for hair follicle regeneration. PlncRNA-1 promoted hair follicle stem cell differentiation via the EZH2/ZEB1/MAPK1 axis, enhancing wound healing. Secretome-based therapies offer a promising multifaceted approach to stimulating hair follicles and promoting hair regeneration, potentially overcoming the limitations and side effects of current treatments like minoxidil and finasteride. Understanding these mechanisms provides valuable insights for future therapeutic development in hair growth disorders.
... (10,11) steroid hormones cause the balding process. (12) Finasteride is a synthetic medication that inhibits the enzyme 5-α-reductase and prevents baldness. However, long-term use of finasteride treatment can have serious side effects (13). ...
Article
Full-text available
Alopecia is a disorder that results in partial or complete shedding of hair from the scalp. Inhibiting the enzyme 5-α-reductase is one modern preventive strategy. By blocking the enzyme 5-α-reductase, testosterone in the circulatory system undergoes conversion into dihydrotestosterone, becoming a more powerful metabolite. Literature: Kushtakudori Ennai, Siddha poly herbal drug is used as an Alopecia medicine mentioned in the literature Prana Rakshamirtha Sindhu. The study aims to evaluate the anti-alopecia properties of nine recognized compounds found in Kushtakudori Ennai. Their interaction with the androgen receptor (PDB code 4K7a) through the use of the Auto doc software and molecular docking was the basis for their activity. Methodology: Autodock 1.5.6., preparation and optimization of three-dimensional structures of compounds, creation of androgen protein structure databases, and ADME-Tox prediction using the pk CSM tool were the stages of research that were carried out. Observation: From the various elements of the polyherbal siddha formulation, a total of nine bioactive lead compounds were solitary. From the reported data of the herbs, the phytochemicals such as Oleic acid, Chebuloside, Friedelin, Maslinic acid, Piperine, Isovitexin, Astragalin, Salsoline and Alangicine. Compounds like Astragalin, Chebuloside, Friedelin, and Piperine reveal a maximum of four to five interactions with the bioactive residues present on the target androgen receptor. Other components such as Isovitexin, Salsoline, Maslinic acid, and Alangicine reveal a maximum of three viable interactions with the target in comparison with the standard drug Finasteride. Conclusion: This suggests that these compounds may impede the binding of native ligands and restrict the process of follicle shrinkage, and these lead to hair fall. Thus, it was determined that the phyto chemical compounds mentioned above might have encouraging anti- alopecia effects.
... (10,11) steroid hormones cause the balding process. (12) Finasteride is a synthetic medication that inhibits the enzyme 5-α-reductase and prevents baldness. However, long-term use of finasteride treatment can have serious side effects (13). ...
Article
Full-text available
Background: In the case of alopecia, the scalp's hair may completely or partially lost. The 5--reductase enzyme has been inhibited as a recent prophylactic treatment. Diahydrotestosterone, a more potent metabolite of testosterone, is produced when the enzyme 5--reductase is inhibited. Literature: Kushtakudori ennai, Siddha poly herbal drug is used as a Alopecia medicine mentioned in the literature Prana rakshamirtha sindhu.This research aimed to test activity of 9 known compounds contained within the herbs of Kushtakudori ennai as anti-alopecia. Methodology: Utilizing molecular docking and the Auto doc program, functionality was determined on their interaction with the androgen receptor (PDB code 4K7a). The steps in the research process were: creating databases of androgen protein structures; creating and perfecting three-dimensional structures of compounds; utilizing Autodock 1.5.6 to dock molecules to the androgen receptor protein; and using the pkCSM tool to estimate ADME-Tox. Observation and Inference: Total of 9 bioactive lead compounds were retrieved from the ingredients present on the polyherbal siddha formulation. From the reported data of the herbs, the phytochemicals such as Oleic acid, Chebuloside, Friedelin, Maslinic acid, Piperine, Isovitexin, Astragalin, Salsoline and Alangicine. The compound’s like Astragalin, Chebuloside, Friedelin and Piperine reveals maximum of four to five interactions with the bioactive residues present on the target androgen receptor. Other components such as Isovitexin, Salsoline, Maslinic acid and Alangicine revels maximum of three viable interactions with the target in comparison with standard drug Finasteride. Conclusion: Based on the results of the computational analysis it was concluded that the bio-active compound’s like Astragalin, Chebuloside, Friedelin, Piperine, Isovitexin, Salsoline, Maslinic acid and Alangicine reveals prominent interaction with active site of the receptor thereby it may hinder the binding of native ligand and also limit the follicle shrinkage and subsequent hair fall process. Hence it was concluded that the aforementioned phytocompounds may exerts promising anti-alopecia activity.
... It is relevant to highlight that the augmented activity of SRD5A2 is connected to enhanced DHT production. This hormone is renowned for its association with activating its receptors in hair follicle cells, resulting in diminished activity [25][26][27]. This observation also establishes a link to the clinical efficacy of finasteride and Fig. 1 Manhattan plot summarising the statistic results for all SNPs studied under all association models to androgenetic alopecia as phenotype dutasteride, as this enzyme plays a vital role in their respective mechanisms of action [28]. ...
Article
Full-text available
Androgenetic alopecia (AGA) is a prevalent, multifactorial form of hair loss involving complex aetiological factors, such as altered androgen regulation and energy metabolism. Existing treatments offer limited success, thus highlighting the need for advanced, personalised therapeutic strategies. This study focuses on correlating the genetic mechanisms of AGA with molecular targets involved in the response to current treatment modalities. An anonymised database including 26,607 patients was subjected to analysis. The dataset included information on patients’ genotypes in 26 single nucleotide polymorphisms (SNPs), specifically, and diagnosed AGA grades, representing a broad range of ethnic backgrounds. In our sample, 64.6% of males and 35.4% of females were diagnosed with female pattern hair loss. This distribution aligns well with prior studies, thus validating the representativeness of our dataset. AGA grading was classified using the Hamilton–Norwood and Ludwig scales, although no association was found to the grade of the disease. SNP association analysis revealed eight SNPs, namely rs13283456 (PTGES2), rs523349 (SRD5A2), rs1800012 (COL1A1), rs4343 (ACE), rs10782665 (PTGFR), rs533116 (PTGDR2), rs12724719 (CRABP2) and rs545659 (PTGDR2), to be statistically significant with a p-value below 0.05. The study establishes a preliminary association between eight specific SNPs and AGA. These genetic markers offer insights into the variability of therapeutic responses, thus underlining the importance of personalised treatment approaches. Our findings show the potential for more targeted research to understand these SNPs’ and further roles in AGA pathophysiology and in modulating treatment response.
Article
Background Menopause refers to the natural process of the “cessation of the menstrual cycle.” This phase predominantly affects aged women and can lead to various symptoms such as hot flashes, insomnia, night sweats, and sexual dysfunction, among others. Unfortunately, many women remain unaware of this condition, and some even choose to overlook the symptoms. However, those who recognize the symptoms consult with a doctor, who may recommend Hormone replacement therapy (HRT). Initially, Hormone replacement therapy (HRT) can be effective, but prolonged use can result in side effects. To mitigate these effects, there is a need to explore and investigate herbal therapies as an alternative treatment for menopausal symptoms. Objective The objective of this review is to explore and summarize various herbs used in managing menopausal symptoms as an alternative to hormone replacement therapy. Methods For this review, we conducted a literature survey spanning from 1998 to 2023. We used keywords such as menopause, endocrinology, hormone replacement therapy, and herbs used for reducing menopausal symptoms to search databases such as Google Scholar, PubMed, and SciDirect. Relevant data were sourced from various journals like Plos One, JAMA, Frontier, Drug in Context, MDPI, Molecules, BMC Women's Health, Research Gate, Heliyon, Elsevier, Taylor & Francis, Nutrients, JMM, Wiley, OXFORD, Hindawi, Clinical Phytoscience, Pharmaceuticals, Phytomedicine, and Menopause: The Journal of The North American Menopause Society. Results The literature review encompassed 40 research articles and 200 review articles, including randomized controlled trials. The findings revealed that several herbal plants, including Curcuma longa, Zingiber officinale, Foeniculum vulgare, Trigonella foenum, Actaea racemosa, Glycyrrhiza glabra, Oenothera biennis, Trifolium pratense, Humulus lupulus, Vitex agnus-castus, Valeriana officinalis, Linum usitatissimum, Cannabis sativa, and Asparagus racemosus, have shown efficacy in treating menopausal symptoms. Conclusion In conclusion, medicinal plants can play a significant role in managing acute menopausal syndrome. The intent of this review is to highlight the most recent research on estrogenic plants for medicinal purposes and their therapeutic impact on cognitive deficiencies brought on by estrogen shortage during menopause and aging.
Article
Introduction: Andropause is a collection of clinical symptoms due to a decrease in testosterone levels below normal limits. Androgenic alopecia is baldness caused by the susceptibility of the follicles to androgen hormones. The aims of study is determining the relationship between androgenic alopecia and andropause in civil servants at the Badung Regency Government Center. Methods: The study design is cross-sectional with descriptive analytic. ADAM questionnaire is used to assessed andropause. Meanwhile, Norwood-Hamilton baldness scale is used to assessed androgenic alopecia. Results: Respondents in this study amounted to 40 people. A total of 27 (67.5%) positive andropause respondents and 13 respondents (33.5%) negative andropause. Meanwhile, 21 respondents (52.1%) were positive for androgenic alopecia and 19 respondents (47.5%) were negative for androgenic alopecia. There was a significant relationship (p<0.001) between andropause and androgenic alopecia. The odd ratio value (OR 95%CI) between andropause and androgenic alopecia is 34.3 (3.726-313.837). Conclusion: Andropause has a significant relationship to androgenic alopecia of civil servants at the Badung Regency Government Center. Pendahuluan: Andropause adalah kumpulan gejala klinis akibat kadar testosteron yang menurun di bawah batas normal. Alopesia androgenik adalah kebotakan yang disebabkan kerentanan folikel terhadap hormon androgen. Tujuan penelitian adalah menganalisis hubungan andropause dengan alopesia androgenik pada aparatur sipil negara di Pusat Pemerintahan Kabupaten Badung. Metode: Rancangan penelitian adalah cross-sectional dengan deskriptif analitik. Kuesioner ADAM digunakan untuk menilai andropause dinilai. Sedangkan, alopesia androgenik dinilai dengan menggunakan skala kebotakan Norwood-Hamilton. Hasil: Responden dalam penelitian ini berjumlah 40 orang. Sebanyak 27 (67,5%) responden positif andropause dan 13 responden (33,5%) negatif andropause. Sementara itu, 21 responden (52,1%) positif alopesia androgenik dan 19 responden (47,5%) negatif alopesia androgenik. Terdapat hubungan yang signifikan (p<0,001) antara andropause dan alopesia androgenik. Adapun nilai odd ratio (OR 95%CI) antara andropause dan alopesia androgenik adalah 34,3 (3,726-313,837). Simpulan: Andropause memiliki hubungan signifikan terhadap alopesia androgenik pada aparatur sipil negara di Pusat Pemerintahan Kabupaten Badung.
Article
Full-text available
Age-related skin changes can be induced by chronological ageing, manifested in subcutaneous fat reduction, and photo-ageing eliciting increased elastotic substance in the upper dermis, destruction of its fibrilar structure, augmented intercellular substance and moderate inflammatory infiltrate. Forty-five biopsy skin samples of the sun-exposed and sun-protected skin were analyzed. The patients were both males and females, aged from 17 to 81 years. The thickness of the epidermal layers and the number of cellular living layers is greater in younger skin. The amount of keratohyaline granules is enlarged in older skin. Dermoepidermal junction is flattened and the presence of elastotic material in the dermis is pronounced with age. The amount of inflammatory infiltrate is increased, the fibrous trabeculae are thickened in older skin and the atrophy of the hypodermis is observed. Chronological ageing alters the fibroblasts metabolism by reducing their life span, capacity to divide and produce collagen. During ageing, the enlargement of collagen fibrils diminishes the skin elasticity.
Article
Full-text available
Unlabelled: The mechanisms by which androgens regulate fat mass are poorly understood. Although testosterone has been reported to increase lipolysis and inhibit lipid uptake, androgen effects on proliferation and differentiation of human mesenchymal stem cells (hMSCs) and preadipocytes have not been studied. Here, we investigated whether dihydrotestosterone (DHT) regulates proliferation, differentiation, or functional maturation of hMSCs and human preadipocytes from different fat depots. DHT (0-30 nM) dose-dependently inhibited lipid accumulation in adipocytes differentiated from hMSCs and downregulated expression of aP2, PPARgamma, leptin, and C/EBPalpha. Bicalutamide attenuated DHT's inhibitory effects on adipogenic differentiation of hMSCs. Adipocytes differentiated in presence of DHT accumulated smaller oil droplets suggesting reduced extent of maturation. DHT decreased the incorporation of labeled fatty acid into triglyceride, and downregulated acetyl CoA carboxylase and DGAT2 expression in adipocytes derived from hMSCs. DHT also inhibited lipid accumulation and downregulated aP2 and C/EBPalpha in human subcutaneous, mesenteric and omental preadipocytes. DHT stimulated forskolin-stimulated lipolysis in subcutaneous and mesenteric preadipocytes and inhibited incorporation of fatty acid into triglyceride in adipocytes differentiated from preadipocytes from all fat depots. Conclusions: DHT inhibits adipogenic differentiation of hMSCs and human preadipocytes through an AR-mediated pathway, but it does not affect the proliferation of either hMSCs or preadipocytes. Androgen effects on fat mass represent the combined effect of decreased differentiation of fat cell precursors, increased lipolysis, and reduced lipid accumulation.
Article
Full-text available
Testosterone therapy increases lean body mass and decreases total fat mass in aging men with low normal testosterone levels. The major challenge is, however, to determine whether the metabolic consequences of testosterone therapy are overall positive. We have previously reported that 6-month testosterone therapy did not improve insulin sensitivity. We investigated the effect of testosterone therapy on regional body fat distribution and on the levels of the insulin-sensitizing adipokine, adiponectin, in aging men with low normal bioavailable testosterone levels. A randomized, double-blinded, placebo-controlled study on 6-month testosterone treatment (gel) in 38 men, aged 60-78 years, with bioavailable testosterone <7.3 nmol/l, and a waist circumference >94 cm. Central fat mass (CFM) and lower extremity fat mass (LEFM) were measured by dual X-ray absorptiometry. Subcutaneous abdominal adipose tissue (SAT), visceral adipose tissue (VAT), and thigh subcutaneous fat area (TFA) were measured by magnetic resonance imaging. Adiponectin levels were measured using an in-house immunofluorometric assay. Coefficients (b) represent the placebo-controlled mean effect of intervention. LEFM was decreased (b = -0.47 kg, P = 0.07) while CFM did not change significantly (b = -0.66 kg, P = 0.10) during testosterone therapy. SAT (b = -3.0%, P = 0.018) and TFA (b = -3.0%, P < 0.001) decreased, while VAT (b = 1.0%, P = 0.54) remained unchanged. Adiponectin levels decreased during testosterone therapy (b = -1.3 mg/l, P = 0.001). Testosterone therapy decreased subcutaneous fat on the abdomen and lower extremities, but visceral fat was unchanged. Moreover, adiponectin levels were significantly decreased during testosterone therapy.
Article
Full-text available
Androgens are thought to have an adverse effect on female scalp hair growth. However, our clinical experience of androgen replacement therapy in women with androgen deficiency, in which hair loss was seldom reported, led us to question this concept. To evaluate the effect of subcutaneous testosterone therapy on scalp hair growth in female patients. A total of 285 women, treated for a minimum of 1year with subcutaneous testosterone implants for symptoms of androgen deficiency, were asked to complete a survey that included questions on scalp and facial hair. Age, body mass index (BMI) and serum testosterone levels were examined. Out of the 285 patients, 76 (27%) reported hair thinning prior to treatment; 48 of these patients (63%) reported hair regrowth on testosterone therapy (responders). Nonresponders (i.e. no reported hair regrowth on therapy) had significantly higher BMIs than responders (P=0·05). Baseline serum testosterone levels were significantly lower in women reporting hair loss prior to therapy than in those who did not (P=0·0001). There was no significant difference in serum testosterone levels, measured 4weeks after testosterone implantation, between responders and nonresponders. No patient in this cohort reported scalp hair loss on testosterone therapy. A total of 262 women (92%) reported some increase in facial hair growth. Subcutaneous testosterone therapy was found to have a beneficial effect on scalp hair growth in female patients treated for symptoms of androgen deficiency. We propose this is due to an anabolic effect of testosterone on hair growth. The fact that no subject complained of hair loss as a result of treatment casts doubt on the presumed role of testosterone in driving female scalp hair loss. These results need to be confirmed by formal measurements of hair growth.
Article
Subcutaneous and visceral fat distribution as related to sex, age, and overweight was studied in 130 subjects and 10 women with Cushing's disease. Fat depots were evaluated by computed tomography at one thoracic and one abdominal level. Adipose tissue (density range −50 to 250 Hansfield units) was highlighted and the fat areas were measured by a laser planimeter. The ratio between subcutaneous and visceral fat areas (S:V ratio) was assumed as an index. Ratios of both nonobese and obese groups were significantly higher in females than in males. Ratios decreased markedly over age 60. There was a significant inverse correlation between age and S:V ratios in females (r = 0.65; p < 0.001) and in males (r = 0.61; p < 0.001). Statistically significant correlations were found between S:V ratios at thoracic and abdominal levels. In Cushing's patients, the S:V ratio at the abdominal level was significantly lower than in controls matched for age, sex, and body mass index.
Article
Aging is associated with a redistribution of body fat including a relative loss of subcutaneous peripheral fat. These changes in body fat can have important clinical consequences since they are linked to increased risk of metabolic complications. The causes and mechanisms of loss of peripheral fat associated with aging are not clear. The aim of this study was to assess whether defects in adipogenesis contribute to fat loss in aging humans, as suggested from animal studies, and to evaluate the role of inflammation on pathogenesis of fat loss.Materials/Methods Preadipocytes isolated from subcutaneous peripheral fat of healthy young and elderly subjects were compared in their ability to replicate and differentiate.ResultsThe results show that both the rate of replication and differentiation of preadipocytes are reduced in older subjects. The reduction in adipogenesis is accompanied by a higher plasma level of the inflammatory marker, soluble tumor necrosis factor receptor 2, and greater release of tumor necrosis factor α from fat tissue.Conclusions Thus, the gradual relative loss of peripheral fat in aging humans may in part result from a defect in adipogenesis, which may be linked to inflammation and increased release of proinflammatory cytokines from fat tissue.
Article
The influence of androgen status on the regulation of lipolysis and number of beta-adrenoceptors in isolated adipocytes was studied in male rats. Castration resulted in decreased catecholamine-induced as well as forskolin-induced lipolysis. beta-adrenoceptor number, examined by a whole cell cyanopindolol binding assay, was also diminished to a similar extent. Testosterone treatment of castrated rats normalized lipolysis as well as beta-adrenoceptor number. These results demonstrate that testosterone stimulates catecholamine-induced lipolysis in vivo by increasing the number of beta-adrenoceptors as well as the activity of adenylate cyclase, confirming previous in vitro studies performed in adipose precursor cells.
Article
To investigate the relation between androgens and hair growth, testosterone-1,2-³H metabolism was assessed under standardized conditions in growing (anagen) and resting (telogen) hair roots from 10 anatomical sites from 4 women and 14 men, 6 of whom had varying degrees of male pattern baldness. A micromethod was developed to quantitate androgen metabolism in only a few hair roots. In all hairs examined, 5α-reduced and 17-ketosteroids were the major metabolites of testosterone. No significant relation was found between androgen-mediated growth of hair and the capacity to form 5α-metabolites, e.g., scalp hair of women performed 5α-reduction to approximately the same degree as beard hair from men. The formation of 17-ketometabolites was decreased in telogen hairs from all body sites, whereas the formation of dihydrotestosterone was decreased in telogen hairs only from the scalp. In general a higher formation of 5α-reduced metabolites and 17-ketosteroid metabolites was observed at all sites of the scalp of bald men as compared to hair obtained from the corresponding sites of women and nonbalding men, and a significantly higher rate of metabolism was found at the frontal area of the bald men. It is not clear at present whether these changes are secondary to the balding process or are related causally to the hair loss. On the basis of these studies it is concluded that regional differences in androgen-mediated hair growth cannot be the result of variations in testosterone metabolism in the hair follicles.
Article
In this study, we have correlated cutaneous apoptosis and proliferation in neonatal mice during hair follicle morphogenesis. We have applied a novel triple- staining technique that uses Ki67 immunoreactivity as a marker of proliferation as well as TUNEL and Hoechst 33342 staining as apoptosis markers. We have also assessed the immunoreactivity of interleukin-1-converting enzyme, caspase 1, a key enzyme in the execution of apoptosis, and of P-cadherin, which has been suggested as a key adhesion receptor in segregating proliferating keratinocytes. The TUNEL data were systematically compared with high resolution light microscopy and transmission electron microscopy data. Virtually all keratinocytes of the developing hair bud were strongly Ki67+, suggesting that the hair bud is not an epidermal invagination but primarily the product of localized keratinocyte proliferation. As hair follicle development advanced, three distinct foci of proliferation became apparent: the distal outer root sheath around the hair canal, the mid outer root sheath, and the proximal hair matrix. Of these proliferating hair follicle keratinocytes only defined subsets expressed P-cadherin. TUNEL+ cells in the hair follicle were not found before stage 5 of murine hair follicle morphogenesis. During the early stages of hair follicle development, interleukin-1-converting enzyme immunoreactivity was present on all keratinocytes, but virtually disappeared from the proximal hair follicle epithelium later on. High resolution light microscopy/transmission electron microscopy revealed scattered and clustered apoptotic keratinocytes in all epithelial hair follicle compartments throughout hair follicle development, including its earliest stages. This highlights striking differences in the demarcation of apoptotic hair follicle keratinocytes between the TUNEL technique and high resolution light microscopy/transmission electron microscopy and suggests a role for apoptosis in sculpting the hair follicle even during early hair follicle development.Keywords: apoptosis, ICE, Ki67, P-cadherin, transmission electron microscopy, TUNEL
Article
The aging global population continues to drive increasing demand for cosmaceuticals and cosmetic surgery among older men and women. Since the discovery in the 1990s that estrogen receptors are present in skin cells and decline in number from the onset of menopause in women, researchers have explored a number of ways in which estrogen can improve skin condition. Skin is estrogen responsive, and several studies now exist to support the antiaging properties of estrogen replacement therapies in postmenopausal women. Both systemic and topical estrogens appear to have positive effects on hormonal aging, increasing skin collagen content, thickness, elasticity and hydration. Estrogen therapies may also improve wound healing and reduce the incidence of wound complications. This review explores the potential for targeted estrogen replacement as a therapeutic option for long-term skin management in postmenopausal women.